Search

Your search keyword '"Lymphoma, T-Cell, Peripheral/drug therapy"' showing total 2 results
Start Over Descriptor "Lymphoma, T-Cell, Peripheral/drug therapy"
2 results on '"Lymphoma, T-Cell, Peripheral/drug therapy"'

1. Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels

Author

Richard Delarue, Marie Parrens, Céline Bossard, Maria Pamela Dobay, Olivier Tournilhac, Bettina Fabiani, Antoine Martin, Edoardo Missiaglia, Laurence Lamant, Mauro Delorenzi, Corinne Haioun, Laurence de Leval, and Philippe Gaulard

Subjects
Immunoconjugates, CD30, T cell, Immunology, Ki-1 Antigen, Biology, Biochemistry, Correlation, immune system diseases, hemic and lymphatic diseases, medicine, Humans, RNA, Messenger, Brentuximab Vedotin, Messenger RNA, integumentary system, Lymphoma, T-Cell, Peripheral, Reproducibility of Results, Cell Biology, Hematology, Molecular biology, Immunohistochemistry, Peripheral, Gene Expression Regulation, Neoplastic, medicine.anatomical_structure, Mrna level, Cancer research, Drug Monitoring/methods, Immunoconjugates/therapeutic use, Immunohistochemistry/methods, Immunohistochemistry/standards, Ki-1 Antigen/genetics, Ki-1 Antigen/metabolism, Lymphoma, T-Cell, Peripheral/drug therapy, Lymphoma, T-Cell, Peripheral/genetics, Lymphoma, T-Cell, Peripheral/metabolism, RNA, Messenger/metabolism, DNA microarray, Drug Monitoring
Abstract

The extended use of Brentuximab-Vedotin was reported for CD30+ non-anaplastic peripheral T-cell lymphomas (PTCLs) with promising efficacy. CD30 status assessment is thus a critical factor for therapeutic decision, but the reliability of immunohistochemistry in evaluating its expression remains to be defined. This prompted us to investigate the correlation between semi-quantitative CD30 protein assessment by immunohistochemistry and mRNA assessment by microarrays, in a cohort of 376 non-cutaneous PTCLs representative of the main entities. By immunohistochemistry, CD30 expression was heterogeneous across and within entities, and significantly associated with large tumor cell size. In addition to 100% anaplastic large cell lymphomas, 57% of other PTCL entities were CD30-positive at a 5% threshold. CD30 protein expression was highly correlated to mRNA levels. mRNA levels were bimodal, separating high from low CD30-expressing PTCL cases. We conclude that immunohistochemistry is a valuable tool in clinical practice to assess CD30 expression in PTCLs.

Published
2014

2. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry

Author

Pedersen, Martin Bjerregaard, Hamilton-Dutoit, Stephen Jacques, Bendix, Knud, Møller, Michael Boe, Nørgaard, Peter, Johansen, Preben, Ralfkiaer, Elisabeth, Brown, Peter De Nully, Hansen, Per Boye, Jensen, Bo Amdi, Madsen, Jakob, Schöllkopf, Claudia, and d'Amore, Francesco

Subjects
Male, Sweden, Aged, 80 and over, Adult, Anaplastic large cell lymphoma, Clinical Trials as Topic, Adolescent, Stem cell transplantation, Middle Aged, Prognosis, Lymphoma, T-Cell, Peripheral/drug therapy, Disease-Free Survival, Cohort Studies, Anaplastic lymphoma kinase, Young Adult, Clinical trials, Treatment Outcome, hemic and lymphatic diseases, Humans, Female, Registries, Peripheral T-cell lymphomas, Aged
Abstract

Clinical trials (CTs) are needed to improve the outcome for peripheral T-cell lymphomas (PTCL), and accrual into CTs is one of the main recommendations in international treatment guidelines. The use of risk-adapted strategies has been suggested as a way to optimize treatment outcome in PTCL. The aim of the present study was to evaluate CT eligibility and selected prognostic indices in a population-based PTCL cohort of 481 PTCL patients identified from the Danish Lymphoma Registry in the period 2000-2010. According to five predefined parameters (age, performance status, P-creatinine, P-ALAT and measurable tumour lesion), patients were subdivided into four groups: 'younger fit', 'elderly fit', 'frail' and 'not CT eligible'. International prognostic index (IPI), prognostic index for T-cell lymphoma (PIT) and anaplastic lymphoma kinase (ALK) protein expression were tested at subtype-specific level. Overall, 41% of the patients were considered eligible for interventional CTs implicating curatively intended multiagent chemotherapy, including, if considered appropriate, consolidating stem cell transplantation (SCT), as part of the upfront management strategy. Moreover, 28% was elderly fit and eligible for interventional CT, including those with SCT as part of the trial design. Approximately 7% were defined as 'too frail' for aggressive treatment schedules, whereas 24% were deemed not to be eligible for any CT. Both overall and progression-free survivals were effectively predicted by IPI and PIT (p

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results